Abstract
The 100,000 Genomes Project (100KGP) diagnosed a quarter of recruited affected participants, but 26% of diagnoses were in genes not on the chosen gene panel(s); with many being de novo variants of high impact. However, assessing biallelic variants without a gene panel is challenging, due to the number of variants requiring scrutiny. We sought to identify potential missed biallelic diagnoses independent of the gene panel applied using GenePy - a whole gene pathogenicity metric.
GenePy scores all variants called in a given individual, incorporating allele frequency, zygosity, and a user-defined deleterious metric (CADD v1.6 applied herein). GenePy then combines all variant scores for individual genes, generating an aggregate score per gene, per participant. We calculated GenePy scores for 2862 recessive disease genes in 78,216 individuals in 100KGP. For each gene, we ranked participant GenePy scores for that gene, and scrutinised affected individuals without a diagnosis whose scores ranked amongst the top-5 for each gene. We assessed these participants’ phenotypes for overlap with the disease gene associated phenotype for which they were highly ranked. Where phenotypes overlapped, we extracted rare variants in the gene of interest and applied phase, ClinVar and ACMG classification looking for putative causal biallelic variants.
3184 affected individuals without a molecular diagnosis had a top-5 ranked GenePy gene score and 682/3184 (21%) had phenotypes overlapping with one of the top-ranking genes. After removing 13 withdrawn participants, in 122/669 (18%) of the phenotype-matched cases, we identified a putative missed diagnosis in a top-ranked gene supported by phasing, ClinVar and ACMG classification. A further 334/669 (50%) of cases have a possible missed diagnosis but require functional validation. Applying GenePy at scale has identified potential diagnoses for 456/3183 (14%) of undiagnosed participants who had a top-5 ranked GenePy score in a recessive disease gene, whilst adding only 1.2 additional variants (per individual) for assessment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
EGS was supported by the Kerkut Charitable Trust, a Foulkes Fellowship from the Foulkes Foundation, and the University of Southampton's Presidential Scholarship Award; HLR and AO'D-L and sequencing were supported by the National Human Genome Research Institute (NHGRI) grant U01HG011755 as part of the GREGoR consortium and HR by NHGRI R01HG009141. DB was generously supported by a National Institute of Health Research (NIHR) Research Professorship RP-2016-07-011. JJA is funded by an NIHR advanced fellowship (NIHR302478).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients included in this study consented to participate in the 100,000 Genomes Project - ethics approval by the Health Research Authority (NRES Committee East of England) REC: 14/EE/1112; IRAS: 166046. The ethical approval letter is available upon request.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Ethics approval and consent to participate All patients included in this study consented to participate in the 100,000 Genomes Project - ethics approval by the Health Research Authority (NRES Committee East of England) REC: 14/EE/1112; IRAS: 166046. The ethical approval letter is available upon request.
Consent for publication Not applicable
Availability of data and material Access to the 100KGP dataset analysed in this study is only available as a registered GeCIP member in the Genomics England Research Environment, but restrictions apply to the availability of these data due to data protection and are not publicly available. Information regarding how to apply for data access is available at the following url: https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access/. All data shared in this manuscript were approved for export by Genomics England. The datasets and code supporting the current study are fully accessible within the Genomics England Research Environment.
Competing interests No competing interest or conflicts to declare.
Funding EGS was supported by the Kerkut Charitable Trust, a Foulkes Fellowship from the Foulkes Foundation, and the University of Southampton’s Presidential Scholarship Award; HLR and AO’D-L and sequencing were supported by the National Human Genome Research Institute (NHGRI) grant U01HG011755 as part of the GREGoR consortium and HR by NHGRI R01HG009141. DB was generously supported by a National Institute of Health Research (NIHR) Research Professorship RP-2016-07-011. JJA is funded by an NIHR advanced fellowship (NIHR302478).
Includes Sarah Ennis' ORCID ID: 0000-0003-2648-0869
Data Availability
Access to the 100KGP dataset analysed in this study is only available as a registered GeCIP member in the Genomics England Research Environment, but restrictions apply to the availability of these data due to data protection and are not publicly available. Information regarding how to apply for data access is available at the following url: https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access/. All data shared in this manuscript were approved for export by Genomics England. The datasets and code supporting the current study are fully accessible within the Genomics England Research Environment.
